以下文章来源于投中网 ，作者黎曼 投中网 . 投中网是领先的创新经济信息服务平台，拥有立体化传播矩阵，为创新经济人群提供深入、独到的智识 和洞见，在私募股权投资行业和创新商业领域拥有权威影响力。官网：www.chinaventure.com.cn 来源丨投中网 全球创投圈又发生荒唐一幕。 14岁时通过组装PC电脑开启职业生涯；17岁为德意志银行创建了世界上首批自动化货币套利交易 系统之一；21岁仍在帝国理工学院就读期间，启动了云计算公司Nivio，并在公司拿下1美元估值后 离开，再度打造了一个名为Shoto的照片分享应用，紧接着才创办Builder.ai。 Duggal以擅长演讲和资本运作著称，被媒体称为"AI界的马斯克"，但其激进风格确实为日后创业埋 下隐患。其合伙人Saurabh Dhoot同样具备技术背景，二人起初为公司命名为Engineer.ai，灵感源 于Duggal在德里大学的经历。他声称目睹非技术背景者开发App的困难，决心打造"自然语言转代 码"的AI平台。早期宣传中，Duggal将这一过程类比为"点披萨"——用户只需描述需求，AI即可自 动生成完整应用。 公司初期定位为中小企业服务，主打低代 ...

Core Viewpoint - HistoSonics is evaluating potential acquisition offers from strategic investors including Medtronic, GE Healthcare, and Johnson & Johnson, with a valuation exceeding $2.5 billion (approximately 18.17 billion RMB), which could become a significant platform acquisition in the interventional oncology space [2][3]. Group 1: Overview of Acquisition Rumors - Several companies are reportedly interested in acquiring HistoSonics, with Citigroup serving as the financial advisor for the transaction [3]. - HistoSonics had considered an IPO but has shifted focus to a sale due to macro market uncertainties [3]. Group 2: Valuation Logic - HistoSonics' technology, Histotripsy, is characterized by its unique non-thermal, non-ionizing, and non-invasive properties, resulting in minimal damage to healthy tissue while maintaining treatment precision [5]. - The clinical outcomes for liver cancer patients show a 12-month local tumor control rate of 90%, and the company has received FDA de novo approval [8]. - HistoSonics is advancing clinical trials for pancreatic cancer treatment, targeting patients who are not surgical candidates, indicating a clear expansion of indications [8][9]. Group 3: Potential Industry Impact of Acquisition - If acquired by Medtronic, it could enhance their minimally invasive tumor surgery portfolio by integrating ablation devices [10]. - GE Healthcare could leverage the real-time imaging guidance of Histotripsy to create a comprehensive diagnostic and treatment loop [10]. - Johnson & Johnson's acquisition could represent a natural progression of their investment in HistoSonics, strengthening their non-invasive solutions for soft tissue and tumor removal [10]. Group 4: Trends to Watch - The approval pace for indications like pancreatic and kidney cancer will influence market entry speed [11]. - The reimbursement system will need to adapt to the new treatment pathway offered by Histotripsy [11]. - The complexity of the device necessitates a structured training program for physicians to facilitate widespread clinical adoption [11]. - A successful acquisition by a major player could trigger accelerated financing and exits in the minimally invasive/non-thermal treatment sector [11].

NEW YORK, March 4, 2025 /PRNewswire/ -- Consolidated Edison, Inc. ("Con Edison") (NYSE: ED) announced today it has agreed to issue 6,300,000 of its common shares.  These common shares are being offered by Barclays under Con Edison's effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC"). The underwriter may offer the common shares in transactions on the New York Stock Exchange LLC, in the over-the-counter market or through negotiated transactions at market price ...